Chromosomal Crossover News and Research

RSS

Acupuncture shows promise in head and neck patients with xerostomia

Acupuncture significantly relieves the symptoms of xerostomia, or dry mouth, compared with oral care education in patients who have undergone radical or adjuvant radiotherapy for head and neck cancer, indicate the results of a randomized crossover trial.

1 Nov 2012

Complix to accelerate development of CPABs against intracellular disease targets

Complix announces that it has been awarded a €1.9 million grant (approximately USD$2.4 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders).

30 Oct 2012

Vitamin-rich berries may help prevent glandular ulcers in horses

Adding sea buckthorn berries to the diet of horses could reduce the incidence of glandular gastric ulcers, report researchers.

24 Oct 2012

Researchers investigate effects of sleep architecture on hunger

A new study shows that both length of time and percentage of overall sleep spent in different sleep stages are associated with decreased metabolic rate, increased hunger, and increased intake of calories (specifically from fat and carbohydrates). The findings suggest an explanation for the association between sleep problems and obesity.

23 Oct 2012

Chronic electrical stimulation may help treat gastroparesis symptoms

Diabetic patients who suffer from a common complication of diabetes called gastroparesis may find that chronic electrical stimulation (ES) at specific acupuncture points could relieve gastroparesis symptoms such as nausea, vomiting, early satiety, abdominal fullness, upper abdominal pain and bloating, according to study results unveiled today at the American College of Gastroenterology's (ACG) 77th Annual Scientific meeting in Las Vegas.

22 Oct 2012

Clinical trial to study immunosuppressant tacrolimus against generics

A new study at the University of Cincinnati seeks to end the questions over generic-vs.-brand for a common immunosuppressive drug for transplant patients, tacrolimus.

20 Oct 2012

Talk explores improved diagnostics for cardiac threat through biomedical imaging

Each year, seemingly healthy people suffer from acute heart attacks, strokes and sudden cardiac death.

20 Oct 2012

Environmental factors affect pneumonia hospitalization in HIV

Hospital admissions for Pneumocystis pneumonia in HIV-infected individuals are significantly more common in the summer months, US research shows.

15 Oct 2012

Three WSU studies could result in new treatments for epilepsy, behavioral disorders

Three studies conducted as part of Wayne State University's Systems Biology of Epilepsy Project (SBEP) could result in new types of treatment for the disease and, as a bonus, for behavioral disorders as well.

12 Oct 2012

Heart drug could ease rare muscle disorder

The anti-arrhythmic drug mexiletine may improve symptoms in patients with nondystrophic myotonias, shows a small randomized trial published in JAMA.

11 Oct 2012

Noven initiates d-Amphetamine Transdermal System Phase 2 study in ADHD

Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced commencement of a Phase 2 study of a d-Amphetamine Transdermal System (d-ATS) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Currently, there is no approved amphetamine-based transdermal treatment option available for ADHD.

3 Oct 2012

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

1 Oct 2012

Crizotinib effectively treats patients with ALK-positive lung cancer

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

MicroDose completes third and final MDT-637 Phase 1 study on RSV infection

MicroDose Therapeutx, Inc., announced today the completion of its third and final Phase 1 clinical study for MDT-637 with its novel inhaled antiviral fusion inhibitor, MDT-637, for the treatment of RSV infection.

29 Sep 2012

Cherry intake reduces risk of gout attacks

A new study found that patients with gout who consumed cherries over a two-day period showed a 35% lower risk of gout attacks compared to those who did not eat the fruit.

28 Sep 2012

Positive results from Galleon GAL-021 second Phase I study on respiratory depression

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing control disorders, today announced that results from a second Phase I clinical study of its investigational drug GAL-021 confirmed previous findings that the drug has dose-dependent effects on respiration.

21 Sep 2012

FDA Division of Neurology Products, CoLucid reach agreement for lasmiditan development strategy

CoLucid Pharmaceuticals, Inc., a privately held biopharmaceutical company, has reached agreement with the Food and Drug Administration's Division of Neurology Products concerning the development strategy for lasmiditan at a recently completed End of Phase 2 meeting.

19 Sep 2012

Trevena to present TRV027 Phase 1 clinical data at 16th Annual Heart Failure Society of America Meeting

Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, today announced that it is presenting a poster featuring Phase 1 clinical data on TRV027 at the 16th Annual Heart Failure Society of America Meeting being held in Seattle, WA, September 9th-12th. Trevena is developing TRV027 for the treatment of acute decompensated heart failure.

7 Sep 2012

Study sheds light on how high-fibre diet affects the gut environment

Savvy consumers and health professionals know that fibre is an essential nutrient associated with important health benefits, yet barriers such as overall poor tolerance to higher-fibre diets may be why average intake is far less than experts recommend.